Molecular Analysis and Modeling of Hepatitis E Virus Helicase and Identification of Novel Inhibitors by Virtual Screening

Figure 1

Mutational analysis of the hepatitis E virus helicase (HEV-hel) domain (nts. 2903-3622). (a) Schematic representation of the HEV-hel domain saturation mutants (Hel-1 through Hel-10; ~72 bases each). (b) Flow cytometry analysis of GFP positive S10-3 cells, showing the replication competence of mutant replicons. Hel-1: pSK-GFP-hel1 (nts. 2903-2974); Hel-2: pSK-GFP-hel2 (nts. 2975-3046); Hel-3: pSK-GFP-hel3 (nts. 3047-3118); Hel-4: pSK-GFP-hel4 (nts. 3119-3190); Hel-5: pSK-GFP-hel5 (nts. 3191-3262); Hel-6: pSK-GFP-hel6 (nts. 3263-3334); Hel-7: pSK-GFP-hel7 (nts. 3335-3406); Hel-8: pSK-GFP-hel8 (nts. 3407-3478); Hel-9: pSK-GFP-hel9 (nts. 3479-3550); Hel-10: pSK-GFP-hel10 (nts. 3551-3622); WT: pSK-GFP (positive control); and GAD: pSK-GFP-GAD (negative control). Data are presented as mean ± standard error of mean (n=3).

(a)

(b)